Publications by authors named "Jolanta M Durski"
Article Synopsis
- The study examines the low tumor doses achieved in non-prostate cancers treated with [Lu]Lu-PSMA radioligand, using a case of renal cell carcinoma as an example.
- Despite high uptake of the imaging agent [Ga]Ga-PSMA-11, treatment with [Lu]Lu-PSMA-I&T resulted in low radiation doses to tumors (0.2-0.5 Gy) and no observable treatment effect.
- The researchers suggest that the ineffective targeting may be due to PSMA receptors being located on new blood vessels rather than on tumor cells, leading to rapid washout; they propose using a radionuclide with a shorter half-life to improve treatment efficacy.
Article Synopsis
- - Redifferentiation therapy (RDT) effectively restores radioactive iodine (RAI) uptake in differentiated thyroid cancer (DTC) patients who previously had RAI refractory disease, enabling further treatment options.
- - In a study of 33 patients at the Mayo Clinic, 57.6% showed restored RAI uptake following RDT, with higher rates in certain subtypes of thyroid cancer, particularly in those with mutant tumors.
- - Despite a lack of significant differences in progression-free survival between redifferentiated and non-redifferentiated groups, RDT led to improved tumor shrinkage, with an additional median reduction of 20% observed at 6 months post-high-dose iodine therapy.
Article Synopsis
- A model developed by Atkins calculates the maximum tolerated activity of 131I based on a 48-hour whole-body retention measurement from a diagnostic scan.
- The authors' practice involves using iodine 123I for staging metastatic thyroid cancer, with scans taken 24 hours after administration.
- They investigated adding a 48-hour 123I whole-body scan to measure retention and apply the Atkins model for estimating the maximum tolerated activity of 131I before treatment.
Objective: The purpose of this study is to determine the efficacy of C-choline PET/CT for the detection of parathyroid adenomas by retrospectively reviewing a large patient population.
Materials And Methods: In this single-institution retrospective study, 7088 C-choline PET/CT scans performed of 2933 men with prostate cancer from January 2005 through February 2016 were evaluated. Patients with suspected parathyroid adenomas were identified through a review of the electronic medical record and relevant imaging.
Background: Graves' ophthalmopathy (GO) develops or worsens in up to one-third of patients treated with radioactive iodine (RAI) for Graves' hyperthyroidism. We sought to identify the prevalence of development or worsening of GO in patients treated with RAI for Graves' hyperthyroidism and to identify the risk factors associated with that outcome.
Methods: We identified a retrospective cohort of consecutive patients treated with RAI at Mayo Clinic (Rochester, MN) between 2005 and 2006.
Objective: To explore the value of (18)F fluorodeoxy-glucose (FDG) positron emission tomography (PET) in Burkitt's lymphoma.
Methods: All Burkitt's lymphoma patients referred for FDG PET or FDG PET/computed tomography (CT) exams at our institution from June 2003 to June 2006 were included. Selected patients were followed and clinical information was reviewed retrospectively.
Purpose: To our knowledge, there are no published data pertinent to the use of [(18F)]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with natural killer (NK)/T-cell lymphoma. The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma.
Patients And Methods: All patients with NK/T-cell lymphoma referred for FDG PET/CT at our institution from July 2001 to July 2006 were retrospectively studied.
In vitro gastrointestinal (GI) bleed testing such as the UltraTag kits has been successfully used for a number of years. None of the research studies identified reported any significant bone marrow and liver uptake. An 80-y-old male patient was admitted to the hospital for rectal bleeding.
View Article and Find Full Text PDF